
Over the last 7 days, the Clinical Research and Equipment industry has dropped 1.2%, driven by Locus Cell declining 11%. In contrast, BioLASCO Taiwan has gained 5.1%. Overall the industry is down 4.1% in 12 months.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 11 Jun 2026 | NT$32.4b | NT$2.7b | -NT$746,869,000.00 | 21.6x | -43.4x | 12.2x |
| Sat, 09 May 2026 | NT$34.1b | NT$2.5b | -NT$764,028,000.00 | 21.6x | -44.7x | 13.5x |
| Mon, 06 Apr 2026 | NT$31.0b | NT$2.5b | -NT$767,579,000.00 | 20.4x | -40.4x | 12.4x |
| Wed, 04 Mar 2026 | NT$32.6b | NT$2.4b | -NT$692,870,000.00 | 19.2x | -47x | 13.4x |
| Fri, 30 Jan 2026 | NT$34.3b | NT$2.4b | -NT$689,929,000.00 | 24x | -49.7x | 14.1x |
| Sun, 28 Dec 2025 | NT$34.7b | NT$2.4b | -NT$670,921,000.00 | 24.1x | -51.7x | 14.2x |
| Tue, 25 Nov 2025 | NT$36.6b | NT$2.4b | -NT$670,921,000.00 | 18.8x | -54.6x | 15x |
| Thu, 23 Oct 2025 | NT$37.3b | NT$2.5b | -NT$870,437,000.00 | 18.4x | -42.8x | 15.2x |
| Sat, 20 Sep 2025 | NT$34.5b | NT$2.5b | -NT$870,437,000.00 | 20x | -39.6x | 14x |
| Mon, 18 Aug 2025 | NT$33.6b | NT$2.5b | -NT$819,216,000.00 | 19.7x | -41x | 13.7x |
| Wed, 16 Jul 2025 | NT$33.2b | NT$2.5b | -NT$600,003,000.00 | 22.4x | -55.4x | 13.5x |
| Fri, 13 Jun 2025 | NT$34.0b | NT$2.5b | -NT$600,003,000.00 | 24.3x | -56.7x | 13.8x |
| Sun, 11 May 2025 | NT$31.1b | NT$2.5b | -NT$539,009,000.00 | 22.8x | -57.7x | 12.6x |
| Tue, 08 Apr 2025 | NT$31.6b | NT$2.5b | -NT$536,440,000.00 | 22.2x | -59x | 12.9x |
| Thu, 06 Mar 2025 | NT$36.4b | NT$2.6b | -NT$854,432,000.00 | 23.6x | -42.6x | 14.2x |
| Sat, 01 Feb 2025 | NT$36.8b | NT$2.6b | -NT$854,432,000.00 | 23.5x | -43.1x | 14.4x |
| Mon, 30 Dec 2024 | NT$34.2b | NT$2.6b | -NT$854,432,000.00 | 23.3x | -40x | 13.3x |
| Wed, 27 Nov 2024 | NT$40.7b | NT$2.6b | -NT$854,432,000.00 | 23.8x | -47.6x | 15.9x |
| Fri, 25 Oct 2024 | NT$42.3b | NT$2.5b | -NT$712,402,000.00 | 24.8x | -59.4x | 16.9x |
| Sun, 22 Sep 2024 | NT$42.3b | NT$2.3b | -NT$836,610,000.00 | 22.1x | -50.6x | 18.6x |
| Tue, 20 Aug 2024 | NT$40.5b | NT$2.3b | -NT$836,610,000.00 | 21.8x | -48.4x | 17.8x |
| Thu, 18 Jul 2024 | NT$44.2b | NT$2.1b | -NT$797,765,000.00 | 33.9x | -55.4x | 20.7x |
| Sat, 15 Jun 2024 | NT$41.6b | NT$2.1b | -NT$797,765,000.00 | 33.1x | -52.1x | 19.5x |
| Mon, 13 May 2024 | NT$39.9b | NT$2.1b | -NT$893,893,000.00 | 32.2x | -44.6x | 18.7x |
| Wed, 10 Apr 2024 | NT$40.3b | NT$2.1b | -NT$903,875,000.00 | 31.3x | -44.6x | 19.1x |
| Fri, 08 Mar 2024 | NT$42.5b | NT$2.1b | -NT$611,249,000.00 | 33.2x | -69.6x | 20.6x |
| Sun, 04 Feb 2024 | NT$43.1b | NT$2.1b | -NT$610,218,000.00 | 33.1x | -70.7x | 20.8x |
| Tue, 02 Jan 2024 | NT$47.8b | NT$2.1b | -NT$610,218,000.00 | 33.3x | -78.4x | 23x |
| Thu, 30 Nov 2023 | NT$49.6b | NT$2.1b | -NT$610,218,000.00 | 33.7x | -81.3x | 23.9x |
| Sat, 28 Oct 2023 | NT$50.0b | NT$2.2b | -NT$497,769,000.00 | 31.8x | -100.4x | 22.5x |
| Mon, 25 Sep 2023 | NT$47.7b | NT$2.2b | -NT$497,769,000.00 | 31.5x | -95.8x | 21.4x |
| Wed, 23 Aug 2023 | NT$43.2b | NT$2.2b | -NT$497,769,000.00 | 30.8x | -86.9x | 19.4x |
| Fri, 21 Jul 2023 | NT$48.2b | NT$2.5b | -NT$274,767,000.00 | 43x | -175.3x | 19.6x |
| Sun, 18 Jun 2023 | NT$48.4b | NT$2.5b | -NT$274,767,000.00 | 44.1x | -176.2x | 19.7x |
-176.2x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | -7.08% | |
| Healthcare | 1.66% | |
| Life Sciences | -1.20% | |
| Clinical Research and Equipment | -1.20% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6662 BioLASCO Taiwan | NT$30.90 | 5.1% +NT$38.4m | -9.1% | PE18.2x | |
| 7607 DuoGenic StemCells | NT$14.55 | 5.4% +NT$22.9m | 47.1% | n/a | |
| 6848 RBC Bioscience | NT$19.70 | 3.1% +NT$8.6m | 15.6% | PE11.9x |